A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity
用户0k7s_zqg7TRs
1个月前
95
10
已关闭
DOI:
其他信息:
J Hou, T Gu, L Dong, J Tian, X Chen, D Liu…
Cancer …, 2026
aacrjournals.org
CEACAM5 and CDH17 are preferentially expressed in gastrointestinal tumors, including more than 95% of colorectal cancers, 80% of gastric and pancreatic cancers, and 70% of cholangiocarcinomas. Moreover, these two molecules are frequently co-expressed in gastrointestinal cancers. Recent advancements in CEACAM5 and CDH17 research have unveiled their potential as the promising targets for developing novel cancer therapeutics. Here we engineered a bispecific antibody (bsAb) capable of simultaneously binding to both …
